Cancer Research UK logo.
SearchDonate
  • Search

A trial of MK-8242 for advanced solid tumours

Overview

Cancer types:

All cancer types

Status:

Closed

Phase:

Phase 1

Details

This trial is looking at a drug called MK-8242 for people who have a solid tumour for which there is no other treatment available. A is any type of cancer other than or .

Some genes help to stop cancer cells growing. They are called tumour suppressor genes. P53 is an important tumour suppressor gene.

A protein called HDM2 stops p53 working. The drug being looked at in this trial blocks HDM2. This allows p53 to work and stops the growth of cancer cells. The drug is called MK-8242.

In some cancers, the p53 gene is abnormal. But in order for MK-8242 to work, it is important that the p53 gene in the cancer cells is normal. The first few people joining this trial will not have their cancer’s p53 gene tested. But people joining the trial later can only take part if tests show that their tumour has a normal p53 gene. Researchers can check this by looking at a sample of the tumour.

Recruitment start: 30 December 2011

Recruitment end: 24 July 2014

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Dr Udai Banerji

Supported by

Experimental Cancer Medicine Centre (ECMC)

Merck Sharp & Dohme Ltd

Last reviewed: 21 September 2014

CRUK internal database number: 9883

The Dangoor Education logo.

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Patient Information Forum. Trusted Information Creator.
Plain English Campaign award.

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.